Microbiotas are a malleable part of ecosystems, including the human ecosystem.
Microorganisms affect not only the chemistry of their specific niche, such as the human gut …

Natural products derived from microorganisms serve as a vital resource of valuable
pharmaceuticals and therapeutic agents. Streptomyces is the most ubiquitous bacterial …

There is a real consensus that new antibiotics are urgently needed and are the best chance
for combating antibiotic resistance. The phylum Actinobacteria is one of the main producers …

Actinobacteria constitute a highly diverse bacterial phylum with an unrivalled metabolic
versatility. They produce most of the clinically used antibiotics and a plethora of other natural …

Bacteria provide a rich source of natural products with potential therapeutic applications,
such as novel antibiotic classes or anticancer drugs. Bioactivity-guided screening of …

Given the increased reporting of multi-resistant bacteria and the shortage of newly approved
medicines, researchers have been looking towards extreme and unusual environments as a …

Actinobacteria are well-recognised biosynthetic factories that produce an extensive
spectrum of secondary metabolites. Recent genomic insights seem to impact the exploitation …

New antifungal drugs are urgently needed to address the emergence and transcontinental
spread of fungal infectious diseases, such as pandrug-resistant Candida auris. Leveraging …

Animals in the wild are able to subsist on pathogen-infected and poisonous food and show
immunity to various diseases. These may be due to their microbiota, yet we have a poor …

Covering: up to 2021 Metagenomics has yielded massive amounts of sequencing data
offering a glimpse into the biosynthetic potential of the uncultivated microbial majority. While …